| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.98 | 0.002 | 0.98 | Potassium channel blocker | |||
| 0.97 | 0.001 | 0.97 | Cathepsin B inhibitor | |||
| 0.968 | 0.001 | 0.968 | Purinergic P2X7 antagonist | |||
| 0.965 | 0.003 | 1 | Cardiotonic | 1 0 DBMET01898 | DBMET01898 | |
| 0.957 | 0.001 | 0.957 | Cathepsin K inhibitor | |||
| 0.952 | 0 | 0.952 | LIM domain kinase 2 inhibitor | |||
| 0.921 | 0.001 | 0.921 | Vasodilator | |||
| 0.895 | 0.001 | 0.895 | Farnesyltransferase inhibitor | |||
| 0.869 | 0.002 | 0.869 | Purinergic P2 antagonist | |||
| 0.864 | 0.002 | 0.864 | Growth factor agonist | |||
| 0.862 | 0.001 | 0.862 | Stem cell growth factor agonist | |||
| 0.822 | 0.002 | 0.822 | Purinergic P2X antagonist | |||
| 0.8 | 0.002 | 0.8 | Nicotinamide phosphoribosyltransferase inhibitor | |||
| 0.782 | 0.001 | 0.782 | Cathepsin S inhibitor | |||
| 0.767 | 0.001 | 0.767 | Nociceptin (N/OFQ) receptor antagonist | |||
| 0.762 | 0.001 | 0.762 | Histamine H3 receptor agonist | |||
| 0.736 | 0 | 0.736 | Potassium channel (Inward rectifier) 11 blocker | |||
| 0.736 | 0.004 | 0.736 | Bronchodilator | |||
| 0.693 | 0.001 | 0.693 | Protease activated receptor 1 antagonist | |||
| 0.686 | 0.003 | 0.686 | TRKC antagonist | |||
| 0.631 | 0.004 | 0.631 | Alpha-N-acetylglucosaminidase inhibitor | 0.357 0.011 DBMET01896 0.549 0.004 DBMET01897 0.538 0.005 DBMET01898 | ||
| 0.641 | 0.014 | 0.909 | Aldehyde oxidase inhibitor | 0.341 0.057 DBMET01896 0.909 0.003 DBMET01897 0.422 0.044 DBMET01898 | DBMET01897 | |
| 0.66 | 0.039 | 0.66 | Antiinflammatory | |||
| 0.611 | 0.006 | 0.611 | GABA C receptor rho-3 antagonist | 0.536 0.017 DBMET01896 0.563 0.012 DBMET01897 0.561 0.013 DBMET01898 | ||
| 0.571 | 0.002 | 0.571 | Nav1.8 sodium channel blocker | |||
| 0.576 | 0.019 | 0.576 | Vasodilator, peripheral | 0.216 0.158 DBMET01896 0.237 0.138 DBMET01897 0.244 0.131 DBMET01898 | ||
| 0.561 | 0.019 | 0.561 | 5 Hydroxytryptamine release stimulant | 0.325 0.063 DBMET01896 0.459 0.034 DBMET01897 0.459 0.034 DBMET01898 | ||
| 0.548 | 0.006 | 0.737 | Peroxidase inhibitor | 0.552 0.006 DBMET01896 0.737 0.002 DBMET01897 0.405 0.02 DBMET01898 | DBMET01897 | |
| 0.536 | 0.005 | 0.536 | Cyclooxygenase 1 inhibitor | |||
| 0.533 | 0.021 | 0.533 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.46 0.055 DBMET01896 0.489 0.039 DBMET01897 0.492 0.037 DBMET01898 | ||
| 0.509 | 0.004 | 0.576 | GABA C receptor agonist | 0.576 0.003 DBMET01896 0.436 0.004 DBMET01897 0.443 0.004 DBMET01898 | DBMET01896 | |
| 0.5 | 0.004 | 0.918 | Alcohol oxidase inhibitor | 0.233 0.005 DBMET01896 0.918 0.002 DBMET01897 0.255 0.005 DBMET01898 | DBMET01897 | |
| 0.469 | 0.001 | 0.469 | CXC chemokine 1 receptor antagonist | |||
| 0.489 | 0.036 | 0.489 | 5 Hydroxytryptamine release inhibitor | 0.351 0.115 DBMET01896 0.42 0.066 DBMET01897 0.422 0.065 DBMET01898 | ||
| 0.493 | 0.062 | 0.493 | Caspase 9 stimulant | 0.439 0.089 DBMET01896 0.41 0.105 DBMET01897 0.43 0.094 DBMET01898 | ||
| 0.435 | 0.004 | 0.435 | CDK9/cyclin T1 inhibitor | |||
| 0.428 | 0.003 | 0.428 | EphA2 antagonist | |||
| 0.443 | 0.02 | 0.753 | Superoxide dismutase inhibitor | 0.269 0.064 DBMET01896 0.753 0.004 DBMET01897 0.343 0.038 DBMET01898 | DBMET01897 | |
| 0.43 | 0.01 | 0.43 | 5 Hydroxytryptamine uptake stimulant | 0.366 0.021 DBMET01896 0.373 0.02 DBMET01897 0.375 0.019 DBMET01898 | ||
| 0.41 | 0.002 | 0.41 | Protease activated receptor antagonist | |||
| 0.403 | 0.003 | 0.403 | Bombesin antagonist | |||
| 0.411 | 0.013 | 0.411 | Dual specificity phosphatase 3 inhibitor | |||
| 0.391 | 0.004 | 0.391 | Falcipain inhibitor | |||
| 0.416 | 0.03 | 0.416 | Vasodilator, coronary | 0.239 0.146 DBMET01896 0.249 0.135 DBMET01897 0.269 0.116 DBMET01898 | ||
| 0.389 | 0.004 | 0.389 | Falcipain 2 inhibitor | |||
| 0.392 | 0.009 | 0.397 | Tyrosine 3 hydroxylase inhibitor | 0.397 0.008 DBMET01896 0.346 0.017 DBMET01897 0.384 0.01 DBMET01898 | DBMET01896 | |
| 0.385 | 0.004 | 0.385 | Ferrochelatase inhibitor | 0.291 0.008 DBMET01896 0.336 0.005 DBMET01897 0.33 0.005 DBMET01898 | ||
| 0.402 | 0.024 | 0.402 | Calcium channel activator | 0.371 0.037 DBMET01896 0.351 0.049 DBMET01897 0.372 0.037 DBMET01898 | ||
| 0.387 | 0.01 | 0.387 | Bone formation stimulant | |||
| 0.389 | 0.023 | 0.389 | DNA synthesis inhibitor | 0.247 0.068 DBMET01896 0.251 0.066 DBMET01897 0.271 0.055 DBMET01898 | ||
| 0.372 | 0.007 | 0.372 | UDP-glucose 4-epimerase inhibitor | 0.313 0.01 DBMET01896 0.317 0.009 DBMET01897 0.299 0.01 DBMET01898 | ||
| 0.356 | 0.004 | 0.752 | Porphobilinogen synthase inhibitor | 0.187 0.014 DBMET01896 0.752 0.002 DBMET01897 0.237 0.009 DBMET01898 | DBMET01897 | |
| 0.358 | 0.009 | 0.358 | Gastrin inhibitor | 0.237 0.096 DBMET01896 0.248 0.081 DBMET01897 0.245 0.085 DBMET01898 | ||
| 0.367 | 0.022 | 0.367 | Cyclic AMP phosphodiesterase inhibitor | 0.169 0.124 DBMET01897 0.161 0.134 DBMET01898 | ||
| 0.352 | 0.008 | 0.534 | Aldehyde dehydrogenase inhibitor | 0.182 0.033 DBMET01896 0.534 0.004 DBMET01897 0.132 0.06 DBMET01898 | DBMET01897 | |
| 0.345 | 0.004 | 0.345 | Potassium channel Kv1.5 blocker | |||
| 0.343 | 0.003 | 0.343 | Thioredoxin inhibitor | |||
| 0.37 | 0.032 | 0.37 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.403 | 0.074 | 0.403 | Histamine release inhibitor | 0.299 0.124 DBMET01897 0.334 0.107 DBMET01898 | ||
| 0.323 | 0.003 | 0.323 | Janus tyrosine kinase 1 inhibitor | |||
| 0.324 | 0.006 | 0.54 | NADH dehydrogenase inhibitor | 0.174 0.013 DBMET01896 0.54 0.003 DBMET01897 0.195 0.011 DBMET01898 | DBMET01897 | |
| 0.34 | 0.022 | 0.34 | Dual specificity phosphatase inhibitor | |||
| 0.311 | 0.003 | 0.311 | Thioredoxin reductase inhibitor | |||
| 0.307 | 0.01 | 0.307 | TRKB antagonist | |||
| 0.307 | 0.01 | 0.307 | Succinate dehydrogenase inhibitor | 0.234 0.028 DBMET01896 0.274 0.016 DBMET01897 0.285 0.013 DBMET01898 | ||
| 0.322 | 0.028 | 0.322 | RNA-directed DNA polymerase inhibitor | 0.233 0.062 DBMET01896 0.257 0.045 DBMET01897 0.262 0.043 DBMET01898 | ||
| 0.323 | 0.031 | 0.323 | Platelet aggregation inhibitor | |||
| 0.346 | 0.066 | 0.346 | Antithrombotic | 0.226 0.148 DBMET01896 | ||
| 0.291 | 0.011 | 0.291 | 5-Lipoxygenase inhibitor | 0.134 0.044 DBMET01896 | ||
| 0.284 | 0.005 | 0.349 | GABA C receptor antagonist | 0.349 0.004 DBMET01896 0.23 0.008 DBMET01897 0.214 0.01 DBMET01898 | DBMET01896 | |
| 0.345 | 0.066 | 0.345 | Cholesterol antagonist | 0.28 0.104 DBMET01897 0.284 0.101 DBMET01898 | ||
| 0.291 | 0.014 | 0.291 | Nitric-oxide synthase stimulant | 0.241 0.039 DBMET01896 0.26 0.026 DBMET01897 0.289 0.014 DBMET01898 | ||
| 0.281 | 0.005 | 0.281 | Triose-phosphate isomerase inhibitor | 0.238 0.008 DBMET01896 0.228 0.008 DBMET01897 0.252 0.007 DBMET01898 | ||
| 0.282 | 0.007 | 0.282 | 5 Hydroxytryptamine 3E antagonist | 0.228 0.029 DBMET01896 0.256 0.014 DBMET01897 0.256 0.013 DBMET01898 | ||
| 0.297 | 0.023 | 0.297 | Diuretic | |||
| 0.314 | 0.05 | 0.325 | Insulysin inhibitor | 0.325 0.045 DBMET01896 0.27 0.079 DBMET01897 0.254 0.093 DBMET01898 | DBMET01896 | |
| 0.311 | 0.049 | 0.311 | Platelet antagonist | |||
| 0.27 | 0.008 | 0.27 | GABA C receptor rho-2 antagonist | 0.2 0.029 DBMET01896 0.23 0.016 DBMET01897 0.232 0.016 DBMET01898 | ||
| 0.27 | 0.009 | 0.27 | Adenylate kinase inhibitor | 0.231 0.011 DBMET01896 0.223 0.012 DBMET01897 0.254 0.01 DBMET01898 | ||
| 0.265 | 0.006 | 0.265 | Janus tyrosine kinase 3 inhibitor | |||
| 0.286 | 0.028 | 0.292 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.292 0.026 DBMET01896 0.233 0.051 DBMET01897 0.256 0.04 DBMET01898 | DBMET01896 | |
| 0.264 | 0.009 | 0.264 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.15 0.026 DBMET01896 0.21 0.014 DBMET01897 0.25 0.01 DBMET01898 | ||
| 0.27 | 0.017 | 0.27 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.259 | 0.011 | 0.259 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | |||
| 0.251 | 0.005 | 0.251 | Tyk2 inhibitor | |||
| 0.246 | 0.005 | 0.246 | CXC chemokine receptor antagonist | |||
| 0.295 | 0.056 | 0.295 | Transcription factor STAT3 inhibitor | |||
| 0.247 | 0.009 | 0.483 | Histidine decarboxylase inhibitor | 0.186 0.014 DBMET01896 0.483 0.003 DBMET01897 0.164 0.017 DBMET01898 | DBMET01897 | |
| 0.276 | 0.04 | 0.276 | Anesthetic general | 0.158 0.105 DBMET01896 0.207 0.071 DBMET01897 0.202 0.073 DBMET01898 | ||
| 0.249 | 0.014 | 0.249 | Cathepsin H inhibitor | 0.119 0.077 DBMET01896 0.162 0.039 DBMET01897 0.162 0.038 DBMET01898 | ||
| 0.233 | 0.001 | 0.233 | Cathepsin F inhibitor | 0.039 0.038 DBMET01896 | ||
| 0.29 | 0.062 | 0.29 | Transcription factor STAT inhibitor | |||
| 0.283 | 0.057 | 0.283 | Interleukin agonist | 0.238 0.088 DBMET01896 0.229 0.095 DBMET01897 0.257 0.074 DBMET01898 | ||
| 0.223 | 0.001 | 0.223 | Dipeptidyl peptidase I inhibitor | |||
| 0.231 | 0.01 | 0.231 | Falcipain 3 inhibitor | 0.136 0.044 DBMET01897 0.108 0.063 DBMET01898 | ||
| 0.223 | 0.005 | 0.223 | GABA C receptor rho-1 antagonist | 0.207 0.007 DBMET01896 0.185 0.011 DBMET01897 0.188 0.01 DBMET01898 | ||
| 0.235 | 0.017 | 0.235 | Cystathionine beta-synthase inhibitor | 0.119 0.058 DBMET01896 0.193 0.026 DBMET01897 0.165 0.035 DBMET01898 | ||
| 0.24 | 0.022 | 0.24 | Insulin secretagoues | |||
| 0.222 | 0.005 | 0.239 | Factor X inhibitor | 0.239 0.005 DBMET01896 | DBMET01896 | |
| 0.216 | 0.004 | 0.216 | Acyl-CoA dehydrogenase inhibitor | 0.151 0.009 DBMET01896 0.159 0.008 DBMET01897 0.15 0.009 DBMET01898 | ||
| 0.218 | 0.009 | 0.488 | Glutamate dehydrogenase inhibitor | 0.158 0.014 DBMET01896 0.488 0.003 DBMET01897 0.162 0.014 DBMET01898 | DBMET01897 | |
| 0.245 | 0.037 | 0.245 | Insulin sensitizer | 0.145 0.14 DBMET01897 | ||
| 0.215 | 0.009 | 0.215 | Creatine kinase inhibitor | 0.165 0.018 DBMET01896 0.182 0.014 DBMET01897 0.192 0.012 DBMET01898 | ||
| 0.223 | 0.02 | 0.223 | Mannose-6-phosphate isomerase inhibitor | 0.152 0.063 DBMET01896 0.187 0.038 DBMET01897 0.193 0.034 DBMET01898 | ||
| 0.232 | 0.03 | 0.232 | Thiol protease inhibitor | 0.123 0.111 DBMET01897 0.12 0.116 DBMET01898 | ||
| 0.211 | 0.01 | 0.211 | Phosphofructokinase-1 inhibitor | 0.168 0.015 DBMET01896 0.181 0.013 DBMET01897 0.189 0.012 DBMET01898 | ||
| 0.218 | 0.018 | 0.218 | Arachidonic acid antagonist | 0.165 0.071 DBMET01896 0.204 0.029 DBMET01897 0.203 0.031 DBMET01898 | ||
| 0.218 | 0.02 | 0.218 | Ephrin antagonist | |||
| 0.282 | 0.084 | 0.282 | Immunostimulant | 0.239 0.101 DBMET01896 | ||
| 0.205 | 0.007 | 0.218 | Carbamoyl phosphate synthetase inhibitor | 0.218 0.006 DBMET01896 0.171 0.009 DBMET01897 0.169 0.009 DBMET01898 | DBMET01896 | |
| 0.277 | 0.08 | 0.277 | Spasmolytic | |||
| 0.259 | 0.065 | 0.259 | 5 Hydroxytryptamine 1E antagonist | 0.217 0.112 DBMET01897 0.247 0.078 DBMET01898 | ||
| 0.206 | 0.013 | 0.206 | 5 Hydroxytryptamine 3A agonist | 0.11 0.065 DBMET01896 0.167 0.027 DBMET01897 0.165 0.028 DBMET01898 | ||
| 0.198 | 0.006 | 0.198 | Biliverdin reductase inhibitor | 0.159 0.009 DBMET01896 0.16 0.008 DBMET01897 0.186 0.006 DBMET01898 | ||
| 0.209 | 0.017 | 0.209 | CF transmembrane conductance regulator agonist | 0.144 0.087 DBMET01896 0.179 0.038 DBMET01897 0.179 0.037 DBMET01898 | ||
| 0.201 | 0.009 | 0.201 | Potassium channel activator | |||
| 0.192 | 0.004 | 0.192 | Ca2+-transporting ATPase inhibitor | 0.164 0.019 DBMET01896 0.181 0.006 DBMET01897 0.178 0.008 DBMET01898 | ||
| 0.236 | 0.049 | 0.236 | Non-steroidal antiinflammatory agent | 0.149 0.115 DBMET01896 | ||
| 0.198 | 0.013 | 0.198 | Interleukin 8 antagonist | |||
| 0.223 | 0.04 | 0.223 | 3C-like protease (Human coronavirus) inhibitor | 0.166 0.078 DBMET01897 0.192 0.056 DBMET01898 | ||
| 0.22 | 0.037 | 0.456 | Amylase inhibitor | 0.456 0.007 DBMET01897 0.15 0.064 DBMET01898 | DBMET01897 | |
| 0.232 | 0.05 | 0.232 | Neurotrophic factor enhancer | 0.196 0.081 DBMET01897 0.19 0.087 DBMET01898 | ||
| 0.285 | 0.103 | 0.285 | Transcription factor NF kappa B inhibitor | |||
| 0.196 | 0.015 | 0.196 | Adenylate cyclase stimulant | 0.175 0.03 DBMET01896 0.176 0.029 DBMET01897 0.177 0.029 DBMET01898 | ||
| 0.214 | 0.036 | 0.214 | Phospholipase C inhibitor | 0.189 0.052 DBMET01896 0.181 0.059 DBMET01897 0.174 0.068 DBMET01898 | ||
| 0.186 | 0.009 | 0.186 | DOPA decarboxylase inhibitor | 0.156 0.018 DBMET01896 0.163 0.016 DBMET01897 0.171 0.013 DBMET01898 | ||
| 0.227 | 0.05 | 0.227 | LIM domain kinase 1 inhibitor | 0.128 0.124 DBMET01896 | ||
| 0.192 | 0.015 | 0.192 | Sphingosine 1-phosphate receptor 5 antagonist | 0.149 0.063 DBMET01896 0.152 0.058 DBMET01897 0.155 0.054 DBMET01898 | ||
| 0.213 | 0.036 | 0.213 | Interferon gamma antagonist | 0.158 0.068 DBMET01896 0.176 0.053 DBMET01897 0.159 0.068 DBMET01898 | ||
| 0.187 | 0.011 | 0.187 | Prolactin inhibitor | 0.089 0.068 DBMET01896 0.151 0.022 DBMET01897 0.131 0.031 DBMET01898 | ||
| 0.207 | 0.031 | 0.207 | Hexokinase inhibitor | 0.135 0.098 DBMET01897 0.134 0.099 DBMET01898 | ||
| 0.206 | 0.032 | 0.206 | Neurotensin receptor agonist | 0.146 0.11 DBMET01896 0.163 0.074 DBMET01897 0.171 0.06 DBMET01898 | ||
| 0.192 | 0.022 | 0.192 | Neuropeptide Y1 antagonist | |||
| 0.187 | 0.018 | 0.348 | Catalase inhibitor | 0.081 0.047 DBMET01896 0.348 0.005 DBMET01897 0.123 0.032 DBMET01898 | DBMET01897 | |
| 0.181 | 0.014 | 0.181 | Sphingosine 1-phosphate receptor 2 antagonist | 0.123 0.089 DBMET01896 0.141 0.054 DBMET01897 0.141 0.054 DBMET01898 | ||
| 0.169 | 0.003 | 0.169 | Cyclin H inhibitor | |||
| 0.174 | 0.012 | 0.174 | Electrolyte absorption antagonist | 0.118 0.038 DBMET01896 0.139 0.024 DBMET01897 0.14 0.024 DBMET01898 | ||
| 0.202 | 0.041 | 0.202 | Cyclooxygenase inhibitor | |||
| 0.169 | 0.01 | 0.186 | Glutamate decarboxylase inhibitor | 0.186 0.008 DBMET01896 0.14 0.015 DBMET01897 0.153 0.013 DBMET01898 | DBMET01896 | |
| 0.296 | 0.139 | 0.491 | Antibacterial | 0.491 0.043 DBMET01896 | DBMET01896 | |
| 0.174 | 0.018 | 0.174 | Gastric antisecretory | |||
| 0.231 | 0.075 | 0.231 | Neuropeptide Y2 antagonist | 0.192 0.134 DBMET01897 0.182 0.156 DBMET01898 | ||
| 0.168 | 0.014 | 0.168 | ErbB-2 antagonist | |||
| 0.171 | 0.018 | 0.171 | Protein kinase C mu inhibitor | |||
| 0.157 | 0.005 | 0.157 | Aldosterone antagonist | 0.052 0.027 DBMET01897 0.043 0.041 DBMET01898 | ||
| 0.171 | 0.019 | 0.171 | Sphingosine 1-phosphate receptor 4 antagonist | 0.107 0.102 DBMET01896 0.119 0.073 DBMET01897 0.129 0.057 DBMET01898 | ||
| 0.178 | 0.027 | 0.203 | Aminopeptidase B inhibitor | 0.203 0.021 DBMET01896 0.155 0.036 DBMET01897 0.172 0.029 DBMET01898 | DBMET01896 | |
| 0.182 | 0.032 | 0.182 | Platelet activating factor antagonist | |||
| 0.16 | 0.01 | 0.16 | Argininosuccinate synthase inhibitor | 0.143 0.012 DBMET01896 0.127 0.014 DBMET01897 0.15 0.011 DBMET01898 | ||
| 0.157 | 0.008 | 0.157 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.103 0.014 DBMET01896 0.127 0.01 DBMET01897 0.12 0.011 DBMET01898 | ||
| 0.192 | 0.044 | 0.192 | ATPase inhibitor | 0.151 0.1 DBMET01897 0.151 0.1 DBMET01898 | ||
| 0.178 | 0.031 | 0.178 | Adenylate cyclase inhibitor | 0.124 0.064 DBMET01896 | ||
| 0.183 | 0.038 | 0.279 | Cell wall synthesis inhibitor | 0.279 0.011 DBMET01896 0.134 0.081 DBMET01897 0.147 0.068 DBMET01898 | DBMET01896 | |
| 0.216 | 0.072 | 0.216 | MAP kinase kinase 2 inhibitor | 0.199 0.082 DBMET01896 0.141 0.129 DBMET01897 | ||
| 0.234 | 0.09 | 0.234 | DNA damaging | |||
| 0.154 | 0.011 | 0.174 | Phenylalanine 4-hydroxylase inhibitor | 0.174 0.009 DBMET01896 0.12 0.018 DBMET01897 0.116 0.019 DBMET01898 | DBMET01896 | |
| 0.151 | 0.009 | 0.151 | Glutamate release inhibitor | 0.087 0.069 DBMET01896 0.122 0.021 DBMET01897 0.113 0.027 DBMET01898 | ||
| 0.207 | 0.065 | 0.207 | I kappa B kinase epsilon inhibitor | 0.143 0.127 DBMET01896 0.152 0.117 DBMET01897 0.138 0.134 DBMET01898 | ||
| 0.164 | 0.023 | 0.164 | Heat shock protein 70 antagonist | 0.147 0.052 DBMET01897 0.145 0.06 DBMET01898 | ||
| 0.144 | 0.004 | 0.144 | Aconitate hydratase inhibitor | 0.093 0.01 DBMET01896 0.118 0.006 DBMET01897 0.106 0.007 DBMET01898 | ||
| 0.146 | 0.009 | 0.146 | NMDA receptor agonist | 0.122 0.013 DBMET01896 0.064 0.041 DBMET01897 0.081 0.028 DBMET01898 | ||
| 0.152 | 0.015 | 0.152 | Acetylcholine release stimulant | 0.129 0.035 DBMET01897 0.127 0.038 DBMET01898 | ||
| 0.193 | 0.057 | 0.193 | Tumour necrosis factor antagonist | 0.161 0.087 DBMET01896 | ||
| 0.158 | 0.022 | 0.158 | HIV-1 integrase (Overall Integration) inhibitor | 0.096 0.058 DBMET01896 0.119 0.04 DBMET01897 0.135 0.031 DBMET01898 | ||
| 0.146 | 0.011 | 0.146 | Histamine H2 receptor antagonist | 0.078 0.07 DBMET01896 | ||
| 0.16 | 0.026 | 0.16 | Photosensitizer | 0.127 0.049 DBMET01896 0.131 0.045 DBMET01897 0.132 0.044 DBMET01898 | ||
| 0.15 | 0.016 | 0.159 | CYP2A6 inhibitor | 0.159 0.014 DBMET01896 0.116 0.028 DBMET01897 0.107 0.033 DBMET01898 | DBMET01896 | |
| 0.173 | 0.041 | 0.173 | Cyclooxygenase 2 inhibitor | |||
| 0.15 | 0.018 | 0.15 | Anabolic | 0.112 0.048 DBMET01896 0.137 0.026 DBMET01897 0.133 0.028 DBMET01898 | ||
| 0.139 | 0.007 | 0.139 | Granulocyte macrophage colony stimulating factor agonist | 0.097 0.039 DBMET01896 0.122 0.015 DBMET01897 0.123 0.014 DBMET01898 | ||
| 0.172 | 0.041 | 0.172 | MAP kinase 3 inhibitor | 0.145 0.076 DBMET01896 | ||
| 0.134 | 0.005 | 0.134 | NMDA receptor glycine site agonist | 0.105 0.014 DBMET01896 0.072 0.034 DBMET01897 0.088 0.023 DBMET01898 | ||
| 0.237 | 0.109 | 0.437 | Lipoxygenase inhibitor | 0.207 0.133 DBMET01896 0.437 0.029 DBMET01897 | DBMET01897 | |
| 0.164 | 0.036 | 0.164 | Antibacterial (Helicobacter pylori) | |||
| 0.133 | 0.005 | 0.133 | Mineralocorticoid receptor antagonist | |||
| 0.142 | 0.015 | 0.142 | Lanosterol 14 alpha demethylase inhibitor | 0.124 0.027 DBMET01896 0.118 0.033 DBMET01897 0.119 0.032 DBMET01898 | ||
| 0.166 | 0.039 | 0.166 | Nav1.6 sodium channel blocker | 0.13 0.082 DBMET01897 | ||
| 0.131 | 0.005 | 0.131 | Potassium channel (Inward rectifier) blocker | |||
| 0.135 | 0.009 | 0.135 | Glycine receptor agonist | 0.122 0.012 DBMET01896 0.108 0.017 DBMET01897 0.097 0.023 DBMET01898 | ||
| 0.144 | 0.022 | 0.144 | Janus tyrosine kinase 2 inhibitor | |||
| 0.166 | 0.044 | 0.166 | Sodium channel (voltage-gated) blocker | |||
| 0.16 | 0.038 | 0.16 | Pregnane X receptor agonist | 0.14 0.073 DBMET01897 0.141 0.072 DBMET01898 | ||
| 0.137 | 0.015 | 0.137 | Aminopeptidase I inhibitor | 0.109 0.023 DBMET01896 0.118 0.02 DBMET01897 0.117 0.021 DBMET01898 | ||
| 0.128 | 0.007 | 0.128 | Potassium channel (ATP-sensitive) blocker | |||
| 0.138 | 0.017 | 0.138 | Glutamate (mGluR7) agonist | 0.095 0.07 DBMET01896 0.116 0.034 DBMET01897 0.111 0.041 DBMET01898 | ||
| 0.15 | 0.031 | 0.15 | Carbonic anhydrase XV inhibitor | 0.115 0.051 DBMET01896 0.118 0.048 DBMET01897 0.118 0.048 DBMET01898 | ||
| 0.166 | 0.049 | 0.166 | Nav1.2 sodium channel blocker | |||
| 0.12 | 0.005 | 0.12 | Exportin-1 inhibitor | 0.08 0.025 DBMET01896 0.101 0.009 DBMET01897 0.096 0.011 DBMET01898 | ||
| 0.173 | 0.057 | 0.173 | Melanin inhibitor | 0.132 0.11 DBMET01896 0.151 0.08 DBMET01897 0.145 0.089 DBMET01898 | ||
| 0.119 | 0.004 | 0.119 | Potassium channel (Inward rectifier) activator | 0.06 0.019 DBMET01897 0.058 0.022 DBMET01898 | ||
| 0.117 | 0.004 | 0.117 | Potassium channel Kv1.1 blocker | 0.044 0.017 DBMET01897 0.044 0.018 DBMET01898 | ||
| 0.12 | 0.007 | 0.12 | Vanilloid 4 agonist | 0.105 0.013 DBMET01897 0.101 0.016 DBMET01898 | ||
| 0.116 | 0.004 | 0.116 | Potassium channel (ATP-sensitive) activator | 0.057 0.019 DBMET01897 0.055 0.022 DBMET01898 | ||
| 0.127 | 0.015 | 0.127 | Glycine receptor antagonist | 0.092 0.041 DBMET01896 0.105 0.028 DBMET01897 0.113 0.022 DBMET01898 | ||
| 0.118 | 0.006 | 0.118 | Elastase inhibitor | |||
| 0.155 | 0.044 | 0.155 | Cyclooxygenase 3 inhibitor | 0.125 0.072 DBMET01897 0.145 0.052 DBMET01898 | ||
| 0.122 | 0.011 | 0.122 | Purinergic P2X1 antagonist | 0.069 0.033 DBMET01896 0.096 0.018 DBMET01897 0.102 0.016 DBMET01898 | ||
| 0.164 | 0.053 | 0.164 | Hemostatic | |||
| 0.134 | 0.024 | 0.134 | Platelet growth factor antagonist | |||
| 0.148 | 0.038 | 0.148 | Microtubule formation inhibitor | 0.118 0.063 DBMET01897 0.12 0.06 DBMET01898 | ||
| 0.114 | 0.004 | 0.114 | Glucose-6-phosphate isomerase inhibitor | 0.086 0.007 DBMET01896 0.1 0.005 DBMET01897 0.092 0.006 DBMET01898 | ||
| 0.144 | 0.035 | 0.144 | TRPA1 agonist | 0.1 0.087 DBMET01896 0.114 0.065 DBMET01897 0.112 0.069 DBMET01898 | ||
| 0.119 | 0.01 | 0.119 | Estrogen-related receptor beta agonist | 0.08 0.066 DBMET01896 0.107 0.018 DBMET01897 0.1 0.025 DBMET01898 | ||
| 0.14 | 0.032 | 0.164 | Carbonic anhydrase III inhibitor | 0.164 0.024 DBMET01896 0.109 0.053 DBMET01897 0.121 0.043 DBMET01898 | DBMET01896 | |
| 0.12 | 0.013 | 0.12 | D-Ala-D-Ala ligase inhibitor | 0.091 0.043 DBMET01896 0.106 0.023 DBMET01897 0.11 0.019 DBMET01898 | ||
| 0.14 | 0.034 | 0.14 | Nav1.5 sodium channel blocker | |||
| 0.155 | 0.049 | 0.155 | Toll-Like receptor 2 antagonist | 0.12 0.077 DBMET01897 0.118 0.08 DBMET01898 | ||
| 0.124 | 0.018 | 0.124 | MAP-kinase-activated kinase 2 inhibitor | |||
| 0.168 | 0.063 | 0.168 | Cytidine deaminase inhibitor | |||
| 0.142 | 0.037 | 0.142 | Mucolytic | 0.098 0.08 DBMET01896 0.115 0.059 DBMET01897 0.115 0.059 DBMET01898 | ||
| 0.141 | 0.037 | 0.141 | Protein kinase C gamma inhibitor | |||
| 0.129 | 0.024 | 0.129 | Histamine N-methyltransferase inhibitor | 0.101 0.045 DBMET01896 0.105 0.041 DBMET01897 0.112 0.036 DBMET01898 | ||
| 0.111 | 0.007 | 0.111 | Glutamate (mGluR6) antagonist | 0.107 0.008 DBMET01896 0.096 0.012 DBMET01897 0.098 0.011 DBMET01898 | ||
| 0.111 | 0.008 | 0.111 | Histamine agonist | 0.05 0.04 DBMET01896 | ||
| 0.11 | 0.006 | 0.11 | Glutamate (mGluR7) antagonist | 0.091 0.017 DBMET01896 0.094 0.014 DBMET01897 0.09 0.017 DBMET01898 | ||
| 0.107 | 0.004 | 0.107 | ADAM10 endopeptidase inhibitor | 0.044 0.012 DBMET01896 | ||
| 0.165 | 0.062 | 0.165 | Acetylcholine M1 receptor antagonist | |||
| 0.137 | 0.037 | 0.137 | AMP-activated protein kinase stimulant | |||
| 0.109 | 0.009 | 0.143 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.143 0.004 DBMET01896 0.097 0.015 DBMET01897 0.105 0.01 DBMET01898 | DBMET01896 | |
| 0.112 | 0.012 | 0.112 | CC chemokine 5 receptor agonist | 0.097 0.025 DBMET01897 0.096 0.026 DBMET01898 | ||
| 0.104 | 0.004 | 0.104 | Histamine H2 receptor agonist | 0.067 0.012 DBMET01896 0.063 0.013 DBMET01897 0.063 0.013 DBMET01898 | ||
| 0.124 | 0.024 | 0.124 | MAP-kinase-activated kinase inhibitor | |||
| 0.113 | 0.014 | 0.113 | Acetylcholine M5 receptor agonist | 0.09 0.026 DBMET01897 0.078 0.036 DBMET01898 | ||
| 0.127 | 0.029 | 0.127 | MAP kinase kinase 1 inhibitor | 0.094 0.064 DBMET01896 0.092 0.068 DBMET01897 | ||
| 0.159 | 0.062 | 0.159 | Protein kinase stimulant | 0.138 0.077 DBMET01896 0.116 0.097 DBMET01897 0.115 0.098 DBMET01898 | ||
| 0.127 | 0.031 | 0.127 | Calcium antagonist | 0.089 0.056 DBMET01897 0.096 0.051 DBMET01898 | ||
| 0.107 | 0.011 | 0.107 | Phospholipase D inhibitor | 0.089 0.023 DBMET01897 0.09 0.023 DBMET01898 | ||
| 0.108 | 0.012 | 0.108 | Androgen agonist | 0.064 0.036 DBMET01897 0.058 0.044 DBMET01898 | ||
| 0.118 | 0.022 | 0.118 | Keratolytic | 0.091 0.037 DBMET01897 0.08 0.048 DBMET01898 | ||
| 0.1 | 0.006 | 0.1 | Alpha-mannosidase inhibitor | 0.061 0.025 DBMET01896 0.072 0.015 DBMET01897 0.077 0.012 DBMET01898 | ||
| 0.133 | 0.04 | 0.136 | Transcription factor STAT6 inhibitor | 0.136 0.036 DBMET01896 0.108 0.085 DBMET01897 0.109 0.083 DBMET01898 | DBMET01896 | |
| 0.195 | 0.103 | 0.195 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.148 0.145 DBMET01898 | ||
| 0.105 | 0.013 | 0.105 | Alpha 2 adrenoreceptor agonist | 0.059 0.043 DBMET01896 | ||
| 0.185 | 0.093 | 0.185 | Histone acetyltransferase inhibitor | 0.171 0.112 DBMET01896 | ||
| 0.141 | 0.049 | 0.141 | Cholesterol synthesis inhibitor | 0.112 0.073 DBMET01897 0.105 0.08 DBMET01898 | ||
| 0.253 | 0.162 | 0.253 | 15-Lipoxygenase inhibitor | 0.217 0.194 DBMET01896 | ||
| 0.127 | 0.036 | 0.153 | Sphingomyelinase inhibitor | 0.153 0.023 DBMET01896 0.099 0.061 DBMET01897 0.103 0.056 DBMET01898 | DBMET01896 | |
| 0.106 | 0.015 | 0.106 | Ornithine carbamoyltransferase inhibitor | 0.099 0.016 DBMET01896 0.086 0.019 DBMET01897 0.102 0.016 DBMET01898 | ||
| 0.11 | 0.02 | 0.11 | Sphingosine 1-phosphate receptor 4 agonist | 0.074 0.041 DBMET01897 0.078 0.038 DBMET01898 | ||
| 0.135 | 0.047 | 0.135 | DNA repair enzyme inhibitor | 0.116 0.082 DBMET01896 0.111 0.094 DBMET01897 0.117 0.078 DBMET01898 | ||
| 0.094 | 0.006 | 0.094 | Dihydroorotate oxidase inhibitor | 0.056 0.037 DBMET01896 0.079 0.011 DBMET01897 0.072 0.015 DBMET01898 | ||
| 0.111 | 0.023 | 0.111 | mTOR complex 2 inhibitor | 0.081 0.066 DBMET01896 0.092 0.044 DBMET01897 0.093 0.042 DBMET01898 | ||
| 0.121 | 0.034 | 0.364 | Alcohol dehydrogenase inhibitor | 0.081 0.078 DBMET01896 0.364 0.004 DBMET01897 0.096 0.056 DBMET01898 | DBMET01897 | |
| 0.113 | 0.028 | 0.113 | Bromodomain-containing protein 2 inhibitor | 0.087 0.062 DBMET01897 | ||
| 0.138 | 0.053 | 0.138 | Vanilloid 1 agonist | 0.121 0.085 DBMET01897 0.125 0.077 DBMET01898 | ||
| 0.098 | 0.014 | 0.098 | MAP kinase kinase 7 inhibitor | 0.088 0.027 DBMET01896 0.088 0.028 DBMET01897 0.087 0.029 DBMET01898 | ||
| 0.106 | 0.023 | 0.106 | GABA aminotransferase inhibitor | 0.085 0.041 DBMET01896 0.086 0.039 DBMET01897 0.096 0.03 DBMET01898 | ||
| 0.12 | 0.036 | 0.12 | Opioid antagonist | |||
| 0.117 | 0.034 | 0.117 | Phosphodiesterase IV inhibitor | |||
| 0.1 | 0.017 | 0.1 | GABA B receptor agonist | 0.092 0.023 DBMET01896 0.085 0.033 DBMET01897 0.095 0.02 DBMET01898 | ||
| 0.099 | 0.016 | 0.346 | Plasminogen activator inhibitor | 0.346 0.003 DBMET01896 | DBMET01896 | |
| 0.24 | 0.157 | 0.24 | Calpain 2 inhibitor | |||
| 0.09 | 0.007 | 0.09 | Mannosidase inhibitor | 0.054 0.022 DBMET01896 0.06 0.017 DBMET01897 0.066 0.013 DBMET01898 | ||
| 0.125 | 0.043 | 0.125 | Cyclin-dependent kinase 9 inhibitor | |||
| 0.087 | 0.005 | 0.087 | Adenylate cyclase 1 inhibitor | 0.055 0.022 DBMET01896 0.065 0.014 DBMET01897 0.067 0.014 DBMET01898 | ||
| 0.197 | 0.116 | 0.197 | Calpain inhibitor | 0.167 0.153 DBMET01898 | ||
| 0.091 | 0.01 | 0.091 | Nicotinic receptor alpha4 subunit antagonist | |||
| 0.086 | 0.005 | 0.086 | Dopamine D5 agonist | 0.059 0.012 DBMET01896 0.069 0.009 DBMET01897 0.07 0.008 DBMET01898 | ||
| 0.107 | 0.026 | 0.107 | Na+ K+ transporting ATPase inhibitor | 0.107 0.025 DBMET01896 0.097 0.035 DBMET01897 0.099 0.033 DBMET01898 | ||
| 0.112 | 0.032 | 0.112 | Ornithine decarboxylase inhibitor | 0.104 0.04 DBMET01896 0.095 0.05 DBMET01897 0.083 0.064 DBMET01898 | ||
| 0.111 | 0.031 | 0.111 | I kappa B kinase inhibitor | |||
| 0.106 | 0.026 | 0.106 | Macrophage colony-stimulating factor 1 receptor antagonist | |||
| 0.086 | 0.006 | 0.086 | Fumarate hydratase inhibitor | 0.063 0.01 DBMET01896 0.068 0.009 DBMET01897 0.075 0.008 DBMET01898 | ||
| 0.133 | 0.054 | 0.133 | Beta amyloid protein antagonist | 0.115 0.072 DBMET01896 | ||
| 0.079 | 0.005 | 0.079 | Alpha 1d adrenoreceptor agonist | 0.042 0.023 DBMET01896 0.061 0.01 DBMET01897 0.062 0.01 DBMET01898 | ||
| 0.09 | 0.016 | 0.09 | Potassium channel (Tandem pore domain) blocker | 0.08 0.035 DBMET01897 0.074 0.051 DBMET01898 | ||
| 0.101 | 0.027 | 0.101 | Caspase 7 inhibitor | 0.079 0.063 DBMET01897 | ||
| 0.083 | 0.01 | 0.083 | Gonadotropin-releasing hormone receptor antagonist | |||
| 0.088 | 0.016 | 0.088 | Bombesin 2 receptor antagonist | 0.046 0.039 DBMET01897 0.045 0.042 DBMET01898 | ||
| 0.122 | 0.049 | 0.122 | Expectorant | 0.095 0.075 DBMET01897 0.088 0.084 DBMET01898 | ||
| 0.086 | 0.014 | 0.086 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.067 0.024 DBMET01897 0.057 0.033 DBMET01898 | ||
| 0.085 | 0.014 | 0.096 | Potassium channel intermediate-conductance Ca-activated blocker | 0.096 0.01 DBMET01896 0.065 0.032 DBMET01897 0.065 0.032 DBMET01898 | DBMET01896 | |
| 0.078 | 0.007 | 0.078 | Pregnane X receptor antagonist | 0.068 0.017 DBMET01897 0.068 0.016 DBMET01898 | ||
| 0.084 | 0.015 | 0.084 | Beta 1 adrenoreceptor antagonist | |||
| 0.082 | 0.013 | 0.082 | Calcium channel P-type blocker | 0.069 0.029 DBMET01897 0.067 0.035 DBMET01898 | ||
| 0.089 | 0.021 | 0.089 | Beta adrenoreceptor antagonist | |||
| 0.126 | 0.058 | 0.126 | Protein kinase (CK2) alpha inhibitor | |||
| 0.074 | 0.008 | 0.074 | Inosine monophosphate dehydrogenase inhibitor | |||
| 0.071 | 0.005 | 0.071 | Glutamate (mGluR8) agonist | 0.056 0.008 DBMET01896 0.059 0.007 DBMET01897 0.071 0.005 DBMET01898 | ||
| 0.071 | 0.005 | 0.071 | Guanylate cyclase inhibitor | 0.063 0.009 DBMET01897 0.059 0.013 DBMET01898 | ||
| 0.086 | 0.02 | 0.247 | Carbonic anhydrase VB inhibitor | 0.064 0.032 DBMET01896 0.247 0.004 DBMET01897 0.065 0.031 DBMET01898 | DBMET01897 | |
| 0.07 | 0.005 | 0.071 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.06 0.007 DBMET01896 0.06 0.007 DBMET01897 0.071 0.005 DBMET01898 | DBMET01898 | |
| 0.208 | 0.143 | 0.208 | 12-Lipoxygenase inhibitor | |||
| 0.082 | 0.018 | 0.082 | MDM2 inhibitor | 0.068 0.043 DBMET01897 0.069 0.041 DBMET01898 | ||
| 0.08 | 0.017 | 0.08 | Transcription factor RelA inhibitor | 0.071 0.028 DBMET01897 0.075 0.023 DBMET01898 | ||
| 0.109 | 0.046 | 0.109 | Interleukin 1 beta converting enzyme inhibitor | |||
| 0.097 | 0.034 | 0.097 | Nicotinic alpha4beta2 receptor antagonist | 0.07 0.063 DBMET01897 0.075 0.056 DBMET01898 | ||
| 0.076 | 0.014 | 0.076 | Thromboxane synthase inhibitor | |||
| 0.074 | 0.013 | 0.074 | Ryanodine receptor antagonist | 0.066 0.023 DBMET01896 0.064 0.028 DBMET01897 0.069 0.019 DBMET01898 | ||
| 0.133 | 0.071 | 0.133 | Sodium channel blocker | |||
| 0.085 | 0.024 | 0.085 | Protein kinase C beta inhibitor | |||
| 0.091 | 0.03 | 0.091 | Amidase inhibitor | |||
| 0.085 | 0.024 | 0.085 | Protease 3C (Human rhinovirus) inhibitor | 0.058 0.056 DBMET01896 0.069 0.038 DBMET01897 0.07 0.036 DBMET01898 | ||
| 0.066 | 0.005 | 0.066 | Kainate receptor agonist | 0.062 0.006 DBMET01896 0.056 0.009 DBMET01897 0.063 0.006 DBMET01898 | ||
| 0.098 | 0.038 | 0.098 | Adrenaline agonist | |||
| 0.069 | 0.009 | 0.069 | Dopamine beta hydroxylase inhibitor | 0.061 0.014 DBMET01896 0.058 0.017 DBMET01897 0.057 0.019 DBMET01898 | ||
| 0.166 | 0.106 | 0.166 | Focal adhesion kinase 2 inhibitor | |||
| 0.084 | 0.024 | 0.084 | 5 Hydroxytryptamine 3 agonist | 0.081 0.026 DBMET01896 0.063 0.045 DBMET01897 0.061 0.048 DBMET01898 | ||
| 0.108 | 0.049 | 0.154 | Nitric-oxide synthase inhibitor | 0.089 0.08 DBMET01896 0.154 0.021 DBMET01897 | DBMET01897 | |
| 0.083 | 0.024 | 0.083 | Cathepsin L inhibitor | |||
| 0.089 | 0.03 | 0.089 | Phosphodiesterase 4B inhibitor | |||
| 0.093 | 0.035 | 0.093 | Interferon agonist | 0.075 0.061 DBMET01897 0.08 0.053 DBMET01898 | ||
| 0.098 | 0.04 | 0.098 | Acetylcholine nicotinic antagonist | |||
| 0.097 | 0.039 | 0.097 | Inducible nitric-oxide synthase inhibitor | |||
| 0.078 | 0.021 | 0.078 | Thromboxane antagonist | |||
| 0.077 | 0.02 | 0.077 | Corticotropin releasing factor 2 receptor antagonist | 0.061 0.044 DBMET01897 0.061 0.044 DBMET01898 | ||
| 0.069 | 0.012 | 0.089 | Immunoglobulin Fc receptor antagonist | 0.089 0.004 DBMET01896 0.06 0.024 DBMET01897 0.062 0.021 DBMET01898 | DBMET01896 | |
| 0.155 | 0.098 | 0.155 | DNA methyltransferase I inhibitor | 0.146 0.108 DBMET01896 | ||
| 0.103 | 0.046 | 0.103 | Phosphodiesterase 6D inhibitor | |||
| 0.07 | 0.014 | 0.07 | Squalene epoxidase inhibitor | 0.055 0.026 DBMET01897 0.049 0.036 DBMET01898 | ||
| 0.066 | 0.01 | 0.066 | Geranyltranstransferase inhibitor | 0.046 0.027 DBMET01896 0.054 0.019 DBMET01897 0.051 0.022 DBMET01898 | ||
| 0.143 | 0.087 | 0.143 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.111 | 0.055 | 0.206 | Urease inhibitor | 0.121 0.044 DBMET01896 0.206 0.009 DBMET01897 0.097 0.07 DBMET01898 | DBMET01897 | |
| 0.074 | 0.019 | 0.079 | Sphingosine kinase 2 inhibitor | 0.079 0.016 DBMET01896 0.056 0.037 DBMET01897 0.055 0.038 DBMET01898 | DBMET01896 | |
| 0.087 | 0.031 | 0.087 | Neuronal nicotinic receptor antagonist | |||
| 0.095 | 0.04 | 0.095 | Carbonic anhydrase XIII inhibitor | 0.075 0.054 DBMET01896 0.07 0.058 DBMET01898 | ||
| 0.173 | 0.118 | 0.173 | Aryl hydrocarbon receptor agonist | 0.145 0.14 DBMET01898 | ||
| 0.073 | 0.019 | 0.073 | Thromboxane A2 antagonist | |||
| 0.096 | 0.042 | 0.114 | Carbonic anhydrase VI inhibitor | 0.114 0.032 DBMET01896 0.073 0.067 DBMET01897 0.085 0.051 DBMET01898 | DBMET01896 | |
| 0.088 | 0.033 | 0.088 | Alpha adrenoreceptor agonist | |||
| 0.058 | 0.004 | 0.058 | Glutamate (mGluR1a) agonist | 0.03 0.009 DBMET01896 0.033 0.007 DBMET01897 0.03 0.009 DBMET01898 | ||
| 0.073 | 0.02 | 0.073 | Protein kinase C theta inhibitor | |||
| 0.07 | 0.017 | 0.07 | Beta 2 adrenoreceptor antagonist | |||
| 0.068 | 0.015 | 0.068 | Lysophosphatidic acid 3 receptor antagonist | 0.057 0.026 DBMET01897 0.062 0.02 DBMET01898 | ||
| 0.078 | 0.025 | 0.078 | Interferon inducer | 0.063 0.047 DBMET01897 0.067 0.039 DBMET01898 | ||
| 0.066 | 0.014 | 0.066 | Histamine H4 receptor antagonist | |||
| 0.119 | 0.067 | 0.119 | Acetylcholine muscarinic antagonist | |||
| 0.095 | 0.044 | 0.095 | Neuropeptide Y antagonist | |||
| 0.06 | 0.009 | 0.06 | Histamine H1 receptor agonist | 0.05 0.018 DBMET01896 0.052 0.015 DBMET01897 0.053 0.014 DBMET01898 | ||
| 0.106 | 0.055 | 0.271 | Xanthine oxidase inhibitor | 0.271 0.01 DBMET01897 | DBMET01897 | |
| 0.082 | 0.033 | 0.082 | Secretase beta inhibitor | |||
| 0.059 | 0.01 | 0.059 | Nerve growth factor antagonist | 0.048 0.021 DBMET01897 0.053 0.014 DBMET01898 | ||
| 0.068 | 0.019 | 0.068 | Nicotinic alpha3beta2 receptor antagonist | 0.053 0.037 DBMET01897 0.058 0.029 DBMET01898 | ||
| 0.054 | 0.006 | 0.054 | Vanilloid 3 antagonist | 0.044 0.015 DBMET01897 0.036 0.032 DBMET01898 | ||
| 0.097 | 0.049 | 0.097 | Androgen antagonist | |||
| 0.059 | 0.011 | 0.103 | Membrane dipeptidase inhibitor | 0.058 0.011 DBMET01896 0.103 0.004 DBMET01897 0.046 0.019 DBMET01898 | DBMET01897 | |
| 0.056 | 0.008 | 0.056 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.037 0.014 DBMET01896 0.045 0.01 DBMET01897 0.049 0.009 DBMET01898 | ||
| 0.062 | 0.015 | 0.062 | Cathepsin L1 inhibitor | |||
| 0.157 | 0.109 | 0.157 | Pyruvate kinase inhibitor | |||
| 0.127 | 0.08 | 0.127 | Toll-Like receptor 9 antagonist | |||
| 0.081 | 0.035 | 0.223 | Carbonic anhydrase V inhibitor | 0.066 0.047 DBMET01896 0.223 0.005 DBMET01897 0.063 0.05 DBMET01898 | DBMET01897 | |
| 0.075 | 0.028 | 0.075 | Carbonic anhydrase stimulant | 0.061 0.04 DBMET01896 0.058 0.043 DBMET01897 0.059 0.041 DBMET01898 | ||
| 0.099 | 0.052 | 0.099 | Bile acid receptor antagonist | 0.088 0.079 DBMET01898 | ||
| 0.086 | 0.04 | 0.086 | Acetylcholine M4 receptor antagonist | |||
| 0.101 | 0.055 | 0.101 | Potassium channel (Ca-activated) activator | |||
| 0.051 | 0.005 | 0.051 | Nicotinic alpha3beta4 receptor agonist | 0.033 0.016 DBMET01896 0.042 0.009 DBMET01897 0.038 0.012 DBMET01898 | ||
| 0.114 | 0.069 | 0.114 | Caspase 3 inhibitor | |||
| 0.053 | 0.007 | 0.053 | Uridine phosphorylase inhibitor | 0.04 0.012 DBMET01897 0.042 0.011 DBMET01898 | ||
| 0.059 | 0.014 | 0.059 | Cytokine production stimulant | 0.051 0.027 DBMET01896 0.049 0.031 DBMET01897 0.049 0.031 DBMET01898 | ||
| 0.1 | 0.055 | 0.1 | Antihistaminic | |||
| 0.092 | 0.046 | 0.092 | Myeloperoxidase inhibitor | 0.083 0.061 DBMET01896 | ||
| 0.156 | 0.112 | 0.17 | DNA methylase inhibitor | 0.17 0.1 DBMET01896 | DBMET01896 | |
| 0.056 | 0.012 | 0.056 | GABA uptake inhibitor | 0.043 0.022 DBMET01897 0.043 0.023 DBMET01898 | ||
| 0.054 | 0.009 | 0.054 | Heme oxygenase inhibitor | 0.047 0.018 DBMET01897 0.046 0.021 DBMET01898 | ||
| 0.085 | 0.04 | 0.085 | Cathepsin G inhibitor | |||
| 0.08 | 0.036 | 0.08 | Carbonic anhydrase VA inhibitor | 0.066 0.051 DBMET01896 0.068 0.048 DBMET01898 | ||
| 0.106 | 0.062 | 0.132 | Beta glucuronidase inhibitor | 0.132 0.036 DBMET01897 0.092 0.083 DBMET01898 | DBMET01897 | |
| 0.062 | 0.019 | 0.062 | Adenosine deaminase inhibitor | 0.062 0.019 DBMET01896 0.051 0.029 DBMET01897 0.051 0.029 DBMET01898 | ||
| 0.058 | 0.015 | 0.07 | Glutamate (mGluR4) antagonist | 0.07 0.01 DBMET01896 0.043 0.031 DBMET01897 0.05 0.021 DBMET01898 | DBMET01896 | |
| 0.074 | 0.031 | 0.074 | Cannabinoid CB1 receptor antagonist | |||
| 0.047 | 0.004 | 0.049 | Purinergic P2Y15 antagonist | 0.049 0.004 DBMET01896 0.041 0.006 DBMET01897 0.041 0.006 DBMET01898 | DBMET01896 | |
| 0.064 | 0.022 | 0.064 | Dipeptidyl peptidase inhibitor | |||
| 0.056 | 0.013 | 0.056 | Dihydropteroate synthase inhibitor | 0.037 0.032 DBMET01896 0.042 0.024 DBMET01897 0.05 0.017 DBMET01898 | ||
| 0.071 | 0.029 | 0.071 | Cyclin-dependent kinase 6 inhibitor | |||
| 0.058 | 0.016 | 0.058 | AICAR transformylase inhibitor | 0.046 0.027 DBMET01897 0.052 0.02 DBMET01898 | ||
| 0.064 | 0.023 | 0.064 | AMPA receptor antagonist | |||
| 0.045 | 0.005 | 0.045 | Histamine H4 receptor agonist | |||
| 0.064 | 0.023 | 0.064 | Epithelial sodium channel blocker | 0.051 0.048 DBMET01897 0.052 0.045 DBMET01898 | ||
| 0.065 | 0.025 | 0.065 | Glucosylceramidase inhibitor | |||
| 0.153 | 0.113 | 0.166 | Psychostimulant | 0.166 0.103 DBMET01896 | DBMET01896 | |
| 0.196 | 0.156 | 0.196 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.052 | 0.012 | 0.052 | Glutamate (mGluR3) antagonist | 0.041 0.02 DBMET01896 0.038 0.024 DBMET01897 0.036 0.027 DBMET01898 | ||
| 0.058 | 0.018 | 0.058 | Oxytocin agonist | 0.038 0.034 DBMET01896 0.048 0.025 DBMET01897 0.049 0.025 DBMET01898 | ||
| 0.102 | 0.062 | 0.102 | Protein kinase (CK2) inhibitor | |||
| 0.062 | 0.022 | 0.062 | Prolyl endopeptidase inhibitor | 0.047 0.04 DBMET01897 | ||
| 0.089 | 0.049 | 0.089 | Glutathione S-transferase inhibitor | 0.081 0.059 DBMET01898 | ||
| 0.057 | 0.018 | 0.057 | Dihydroorotase inhibitor | 0.043 0.033 DBMET01897 | ||
| 0.113 | 0.074 | 0.117 | Alkylator | 0.117 0.071 DBMET01896 0.098 0.091 DBMET01898 | DBMET01896 | |
| 0.086 | 0.046 | 0.086 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.075 0.056 DBMET01898 | ||
| 0.06 | 0.022 | 0.06 | Topoisomerase II beta inhibitor | 0.045 0.043 DBMET01897 | ||
| 0.062 | 0.024 | 0.062 | Glycine transporter 2 inhibitor | |||
| 0.043 | 0.006 | 0.043 | Nicotinic alpha4beta2 receptor agonist | 0.028 0.02 DBMET01896 0.035 0.012 DBMET01897 0.032 0.014 DBMET01898 | ||
| 0.051 | 0.014 | 0.051 | Phosphoglycerate kinase inhibitor | 0.034 0.026 DBMET01896 0.038 0.021 DBMET01897 0.037 0.022 DBMET01898 | ||
| 0.042 | 0.005 | 0.042 | Inosine monophosphate dehydrogenase 2 inhibitor | |||
| 0.041 | 0.004 | 0.041 | Glutaminyl-peptide cyclotransferase inhibitor | |||
| 0.091 | 0.054 | 0.091 | Histamine antagonist | |||
| 0.056 | 0.02 | 0.056 | CC chemokine 4 receptor antagonist | |||
| 0.042 | 0.006 | 0.042 | MAP3K8 inhibitor | 0.028 0.024 DBMET01896 0.031 0.015 DBMET01897 0.028 0.022 DBMET01898 | ||
| 0.051 | 0.015 | 0.061 | Vascular adhesion protein 1 inhibitor | 0.061 0.009 DBMET01896 | DBMET01896 | |
| 0.074 | 0.039 | 0.074 | Nav1.7 sodium channel blocker | |||
| 0.043 | 0.007 | 0.043 | LFA antagonist | |||
| 0.068 | 0.032 | 0.068 | Glutamate (mGluR1) antagonist | |||
| 0.067 | 0.031 | 0.067 | Heat shock protein 90 beta antagonist | |||
| 0.043 | 0.008 | 0.043 | Glutamate (mGluR3) agonist | 0.042 0.008 DBMET01896 0.037 0.014 DBMET01897 0.037 0.013 DBMET01898 | ||
| 0.065 | 0.03 | 0.065 | Beta 2 adrenoreceptor agonist | |||
| 0.083 | 0.048 | 0.083 | Macrophage migration inhibitory factor inhibitor | |||
| 0.052 | 0.017 | 0.052 | Thymidine kinase inhibitor | 0.041 0.028 DBMET01897 0.041 0.028 DBMET01898 | ||
| 0.039 | 0.005 | 0.039 | Hedgehog signaling activator | 0.033 0.008 DBMET01897 0.031 0.011 DBMET01898 | ||
| 0.071 | 0.036 | 0.071 | Aryl hydrocarbon receptor antagonist | |||
| 0.05 | 0.015 | 0.058 | Arginase inhibitor | 0.058 0.011 DBMET01896 0.038 0.024 DBMET01897 0.039 0.023 DBMET01898 | DBMET01896 | |
| 0.114 | 0.08 | 0.114 | Cholinergic antagonist | |||
| 0.064 | 0.031 | 0.064 | Fatty acid synthase inhibitor | |||
| 0.038 | 0.004 | 0.038 | Vanilloid 2 agonist | 0.025 0.017 DBMET01896 0.033 0.007 DBMET01897 0.031 0.008 DBMET01898 | ||
| 0.04 | 0.006 | 0.04 | Potassium channel (Inward rectifier) 1 blocker | |||
| 0.052 | 0.019 | 0.068 | Glutamate (mGluR group III) antagonist | 0.068 0.01 DBMET01896 0.046 0.027 DBMET01898 | DBMET01896 | |
| 0.066 | 0.033 | 0.066 | Cyclin D1 inhibitor | |||
| 0.041 | 0.008 | 0.041 | CXC chemokine 2 receptor antagonist | |||
| 0.045 | 0.013 | 0.064 | Potassium channel small-conductance Ca-activated activator | 0.064 0.008 DBMET01896 0.031 0.022 DBMET01897 0.032 0.021 DBMET01898 | DBMET01896 | |
| 0.057 | 0.024 | 0.057 | HCV NS3/NS4A protease inhibitor | |||
| 0.111 | 0.079 | 0.111 | Acetylcholine antagonist | |||
| 0.036 | 0.004 | 0.036 | Carbonic anhydrase X inhibitor | 0.021 0.007 DBMET01896 0.028 0.005 DBMET01897 0.029 0.004 DBMET01898 | ||
| 0.036 | 0.004 | 0.036 | Carbonic anhydrase VIII inhibitor | 0.021 0.007 DBMET01896 0.028 0.005 DBMET01897 0.029 0.004 DBMET01898 | ||
| 0.113 | 0.081 | 0.113 | MAP kinase kinase inhibitor | |||
| 0.038 | 0.006 | 0.038 | Estrogen-related receptor gamma antagonist | 0.032 0.012 DBMET01897 0.032 0.012 DBMET01898 | ||
| 0.051 | 0.02 | 0.051 | Glutamate (mGluR1a) antagonist | |||
| 0.119 | 0.088 | 0.284 | Alkaline phosphatase inhibitor | 0.284 0.014 DBMET01897 | DBMET01897 | |
| 0.131 | 0.1 | 0.131 | Phospholipase A2 inhibitor | |||
| 0.058 | 0.028 | 0.058 | Diacylglycerol O-acyltransferase inhibitor | |||
| 0.042 | 0.012 | 0.042 | Tryptophan 5 hydroxylase inhibitor | 0.034 0.03 DBMET01897 0.034 0.03 DBMET01898 | ||
| 0.036 | 0.007 | 0.036 | Nicotinic acid receptor 2 antagonist | 0.029 0.014 DBMET01897 0.031 0.012 DBMET01898 | ||
| 0.034 | 0.005 | 0.034 | Complement factor 1s inhibitor | 0.034 0.005 DBMET01896 0.029 0.01 DBMET01897 0.032 0.006 DBMET01898 | ||
| 0.063 | 0.034 | 0.063 | Sphingosine kinase inhibitor | 0.062 0.035 DBMET01896 | ||
| 0.043 | 0.014 | 0.043 | Free fatty acid receptor 1 antagonist | 0.032 0.026 DBMET01897 | ||
| 0.074 | 0.045 | 0.074 | Orexin receptor 1 antagonist | |||
| 0.045 | 0.017 | 0.045 | Retinoid X receptor antagonist | 0.036 0.03 DBMET01897 | ||
| 0.06 | 0.032 | 0.06 | 5 Hydroxytryptamine 7 agonist | |||
| 0.116 | 0.088 | 0.116 | NADPH oxidase inhibitor | |||
| 0.255 | 0.227 | 0.255 | MAP kinase 1 inhibitor | |||
| 0.051 | 0.023 | 0.051 | Fructose-1,6-bisphosphatase inhibitor | 0.045 0.03 DBMET01898 | ||
| 0.052 | 0.024 | 0.052 | Glutamate (mGluR5) agonist | |||
| 0.046 | 0.019 | 0.046 | AMPA 4 receptor antagonist | 0.044 0.02 DBMET01896 0.037 0.032 DBMET01898 | ||
| 0.035 | 0.008 | 0.035 | Lysophosphatidic acid receptor 1 agonist | 0.029 0.012 DBMET01897 0.029 0.012 DBMET01898 | ||
| 0.056 | 0.03 | 0.056 | Heparanase inhibitor | |||
| 0.097 | 0.07 | 0.097 | MAP kinase kinase kinase inhibitor | |||
| 0.041 | 0.015 | 0.041 | Ceramide glucosyltransferase inhibitor | 0.033 0.03 DBMET01897 | ||
| 0.047 | 0.021 | 0.047 | Angiotensin AT1 receptor antagonist | |||
| 0.043 | 0.017 | 0.043 | Delayed rectifier potassium channel blocker | |||
| 0.133 | 0.107 | 0.142 | Heat shock protein 90 alpha antagonist | 0.142 0.095 DBMET01896 | DBMET01896 | |
| 0.064 | 0.038 | 0.064 | Histone deacetylase SIRT3 inhibitor | 0.058 0.054 DBMET01898 | ||
| 0.062 | 0.037 | 0.062 | Phosphodiesterase 1A inhibitor | |||
| 0.039 | 0.014 | 0.039 | Protein kinase (CK2) beta inhibitor | 0.031 0.03 DBMET01897 0.031 0.03 DBMET01898 | ||
| 0.048 | 0.022 | 0.048 | GABA B receptor antagonist | |||
| 0.04 | 0.015 | 0.04 | Retinoid X alpha receptor antagonist | 0.032 0.027 DBMET01897 | ||
| 0.051 | 0.026 | 0.099 | Thymidylate synthase inhibitor | 0.099 0.004 DBMET01897 0.042 0.039 DBMET01898 | DBMET01897 | |
| 0.029 | 0.004 | 0.029 | Egl nine homolog 2 inhibitor | |||
| 0.053 | 0.028 | 0.053 | Glutamate (mGluR group I) agonist | |||
| 0.058 | 0.034 | 0.058 | Leukotriene C antagonist | |||
| 0.071 | 0.047 | 0.071 | Prostaglandin-E synthase inhibitor | |||
| 0.064 | 0.04 | 0.064 | Phosphodiesterase 1C inhibitor | 0.063 0.042 DBMET01896 | ||
| 0.064 | 0.041 | 0.064 | Acetylcholine M2 receptor antagonist | |||
| 0.049 | 0.026 | 0.049 | Purinergic P2X4 antagonist | |||
| 0.061 | 0.037 | 0.061 | Sphingosine 1-phosphate receptor 3 antagonist | |||
| 0.043 | 0.02 | 0.043 | Farnesoid X receptor agonist | |||
| 0.104 | 0.081 | 0.104 | Proteasome inhibitor | |||
| 0.043 | 0.02 | 0.064 | Diamine oxidase inhibitor | 0.064 0.008 DBMET01896 0.034 0.031 DBMET01898 | DBMET01896 | |
| 0.072 | 0.049 | 0.072 | Calcium channel L-type blocker | |||
| 0.089 | 0.067 | 0.089 | Protein kinase C zeta inhibitor | |||
| 0.033 | 0.011 | 0.033 | NMDA receptor glycine site antagonist | |||
| 0.037 | 0.015 | 0.037 | ATR kinase inhibitor | |||
| 0.057 | 0.035 | 0.057 | Sphingosine 1-phosphate receptor 1 antagonist | |||
| 0.026 | 0.004 | 0.026 | Telomerase stimulant | 0.02 0.008 DBMET01896 0.023 0.005 DBMET01897 0.022 0.006 DBMET01898 | ||
| 0.064 | 0.042 | 0.064 | 5 Hydroxytryptamine 2A agonist | |||
| 0.042 | 0.02 | 0.042 | CF transmembrane conductance regulator antagonist | |||
| 0.031 | 0.01 | 0.031 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.027 0.017 DBMET01897 0.027 0.017 DBMET01898 | ||
| 0.031 | 0.01 | 0.031 | Glucosylceramidase stimulant | 0.026 0.022 DBMET01897 0.026 0.025 DBMET01898 | ||
| 0.056 | 0.034 | 0.057 | Lysine-specific demethylase 1A inhibitor | 0.057 0.033 DBMET01896 | DBMET01896 | |
| 0.06 | 0.038 | 0.06 | Botulinum neurotoxin type A inhibitor | 0.055 0.046 DBMET01896 | ||
| 0.07 | 0.049 | 0.07 | Cannabinoid receptor antagonist | |||
| 0.03 | 0.009 | 0.03 | Acid ceramidase inhibitor | 0.025 0.019 DBMET01897 0.028 0.012 DBMET01898 | ||
| 0.03 | 0.009 | 0.03 | Glutamate (mGluR1) agonist | 0.029 0.011 DBMET01896 0.023 0.02 DBMET01897 0.027 0.013 DBMET01898 | ||
| 0.087 | 0.067 | 0.087 | Polo-like kinase-1 inhibitor | |||
| 0.036 | 0.015 | 0.036 | Lysophosphatidic acid 2 receptor antagonist | |||
| 0.042 | 0.022 | 0.042 | 5 Hydroxytryptamine 2B agonist | |||
| 0.035 | 0.015 | 0.035 | Epoxide hydrolase 1 inhibitor | 0.028 0.027 DBMET01897 0.031 0.02 DBMET01898 | ||
| 0.048 | 0.028 | 0.048 | CDK7/cyclin H inhibitor | |||
| 0.028 | 0.008 | 0.028 | Imidazoline I1 receptor antagonist | 0.02 0.015 DBMET01897 0.02 0.015 DBMET01898 | ||
| 0.026 | 0.006 | 0.026 | Cyclin T1 inhibitor | 0.018 0.013 DBMET01897 0.017 0.014 DBMET01898 | ||
| 0.059 | 0.039 | 0.166 | Xanthine dehydrogenase inhibitor | 0.166 0.006 DBMET01897 | DBMET01897 | |
| 0.037 | 0.017 | 0.037 | Adenosine uptake inhibitor | 0.034 0.026 DBMET01898 | ||
| 0.04 | 0.021 | 0.04 | Integrin alpha2 antagonist | 0.036 0.027 DBMET01898 | ||
| 0.026 | 0.006 | 0.026 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.021 0.013 DBMET01897 0.021 0.013 DBMET01898 | ||
| 0.049 | 0.03 | 0.049 | Potassium channel Kv1.3 blocker | |||
| 0.03 | 0.011 | 0.038 | Thymidine phosphorylase inhibitor | 0.038 0.007 DBMET01896 0.026 0.019 DBMET01897 0.029 0.013 DBMET01898 | DBMET01896 | |
| 0.038 | 0.019 | 0.038 | Glucose-dependent insulinotropic receptor agonist | |||
| 0.031 | 0.012 | 0.031 | Sodium/glucose cotransporter 2 inhibitor | |||
| 0.075 | 0.057 | 0.075 | Sphingosine 1-phosphate receptor antagonist | |||
| 0.046 | 0.028 | 0.046 | Beta adrenoreceptor agonist | |||
| 0.036 | 0.018 | 0.036 | Dipeptidyl peptidase II inhibitor | 0.031 0.025 DBMET01896 | ||
| 0.023 | 0.005 | 0.023 | Lysophosphatidic acid receptor 3 agonist | 0.017 0.006 DBMET01897 0.016 0.007 DBMET01898 | ||
| 0.032 | 0.014 | 0.032 | Lysine carboxypeptidase inhibitor | 0.027 0.019 DBMET01896 0.026 0.019 DBMET01897 0.026 0.019 DBMET01898 | ||
| 0.023 | 0.005 | 0.023 | Methylmalonyl-CoA mutase inhibitor | 0.019 0.01 DBMET01896 0.021 0.007 DBMET01897 0.021 0.007 DBMET01898 | ||
| 0.036 | 0.018 | 0.036 | Melatonin receptor 1A agonist | |||
| 0.039 | 0.021 | 0.039 | Retinoid X alpha receptor agonist | |||
| 0.026 | 0.009 | 0.026 | Isoleucine-tRNA ligase inhibitor | 0.024 0.012 DBMET01896 0.022 0.016 DBMET01897 0.024 0.013 DBMET01898 | ||
| 0.075 | 0.057 | 0.075 | Estrogen receptor alpha antagonist | |||
| 0.035 | 0.017 | 0.035 | Acetylcholine M4 receptor agonist | |||
| 0.062 | 0.045 | 0.192 | Carbonic anhydrase inhibitor | 0.192 0.01 DBMET01897 | DBMET01897 | |
| 0.056 | 0.038 | 0.157 | Carbonic anhydrase I inhibitor | 0.157 0.009 DBMET01897 | DBMET01897 | |
| 0.047 | 0.029 | 0.047 | Purinergic P2Y antagonist | |||
| 0.035 | 0.018 | 0.035 | ATP citrate lysase inhibitor | |||
| 0.061 | 0.044 | 0.061 | Heme oxygenase stimulant | |||
| 0.065 | 0.048 | 0.065 | Orexin receptor antagonist | |||
| 0.025 | 0.008 | 0.025 | Neuraminidase (Influenza B) inhibitor | 0.021 0.015 DBMET01897 0.021 0.014 DBMET01898 | ||
| 0.1 | 0.083 | 0.1 | Anesthetic local | |||
| 0.023 | 0.007 | 0.023 | Antibiotic Anthracycline-like | 0.019 0.012 DBMET01897 0.019 0.013 DBMET01898 | ||
| 0.063 | 0.047 | 0.063 | Beta 3 adrenoreceptor antagonist | |||
| 0.043 | 0.027 | 0.043 | Toll-Like receptor 2 agonist | 0.039 0.03 DBMET01898 | ||
| 0.021 | 0.005 | 0.021 | Thromboxane A2 agonist | 0.017 0.009 DBMET01897 0.02 0.006 DBMET01898 | ||
| 0.029 | 0.013 | 0.029 | Sodium/glucose cotransporter inhibitor | |||
| 0.024 | 0.008 | 0.024 | Retinoid X beta receptor antagonist | 0.022 0.012 DBMET01896 0.021 0.014 DBMET01897 | ||
| 0.055 | 0.039 | 0.176 | Carbonic anhydrase IX inhibitor | 0.176 0.01 DBMET01897 | DBMET01897 | |
| 0.026 | 0.01 | 0.026 | Protease (Human cytomegalovirus) inhibitor | 0.02 0.018 DBMET01898 | ||
| 0.024 | 0.009 | 0.024 | Progesterone agonist | |||
| 0.023 | 0.008 | 0.023 | Alpha 2a adrenoreceptor agonist | 0.018 0.012 DBMET01896 0.015 0.014 DBMET01898 | ||
| 0.048 | 0.033 | 0.048 | Antimetabolite | 0.043 0.037 DBMET01896 | ||
| 0.026 | 0.011 | 0.026 | Prostaglandin F2 alpha agonist | 0.021 0.018 DBMET01897 | ||
| 0.019 | 0.004 | 0.019 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.016 0.006 DBMET01896 0.015 0.006 DBMET01897 0.014 0.007 DBMET01898 | ||
| 0.033 | 0.019 | 0.033 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.04 | 0.026 | 0.04 | Urate transporter 1 inhibitor | |||
| 0.053 | 0.038 | 0.053 | Toll-Like receptor 8 antagonist | |||
| 0.056 | 0.042 | 0.056 | EphB4 antagonist | |||
| 0.051 | 0.037 | 0.051 | Carbonic anhydrase XII inhibitor | |||
| 0.023 | 0.009 | 0.023 | Toll-Like receptor 8 agonist | |||
| 0.068 | 0.054 | 0.068 | Benzodiazepine agonist | |||
| 0.022 | 0.008 | 0.022 | Nicotinic acid receptor 1 antagonist | 0.016 0.014 DBMET01897 0.016 0.014 DBMET01898 | ||
| 0.03 | 0.017 | 0.03 | 5 Hydroxytryptamine 6 agonist | |||
| 0.018 | 0.004 | 0.018 | Glutamate (mGluR6) agonist | 0.017 0.005 DBMET01896 0.014 0.007 DBMET01897 0.018 0.004 DBMET01898 | ||
| 0.096 | 0.082 | 0.096 | GABA receptor agonist | |||
| 0.02 | 0.007 | 0.02 | Nicotinic alpha4 receptor agonist | 0.015 0.013 DBMET01897 | ||
| 0.02 | 0.007 | 0.02 | Purinergic P2Y1 agonist | 0.017 0.009 DBMET01896 0.017 0.009 DBMET01897 0.018 0.008 DBMET01898 | ||
| 0.073 | 0.06 | 0.073 | Glutamate receptor agonist | |||
| 0.087 | 0.074 | 0.087 | Potassium channel (Voltage-sensitive) activator | |||
| 0.122 | 0.11 | 0.123 | Heat shock protein 90 antagonist | 0.123 0.109 DBMET01896 | DBMET01896 | |
| 0.039 | 0.026 | 0.039 | MAP3K5 inhibitor | |||
| 0.018 | 0.005 | 0.018 | Carbonic anhydrase XI inhibitor | 0.014 0.008 DBMET01897 0.016 0.006 DBMET01898 | ||
| 0.037 | 0.024 | 0.037 | Kainate receptor 2 antagonist | |||
| 0.033 | 0.02 | 0.033 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.043 | 0.03 | 0.043 | Glutamate (mGluR group III) agonist | |||
| 0.038 | 0.026 | 0.038 | G protein-coupled receptor agonist | |||
| 0.032 | 0.02 | 0.032 | Cholesterol ester transfer protein antagonist | |||
| 0.035 | 0.023 | 0.035 | Angiotensin II receptor antagonist | |||
| 0.036 | 0.024 | 0.036 | Retinoid X receptor agonist | |||
| 0.081 | 0.069 | 0.081 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | |||
| 0.028 | 0.016 | 0.028 | Integrin alpha2beta1 antagonist | 0.025 0.02 DBMET01898 | ||
| 0.025 | 0.013 | 0.025 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.023 0.017 DBMET01898 | ||
| 0.022 | 0.011 | 0.022 | Factor XIII inhibitor | 0.021 0.013 DBMET01898 | ||
| 0.031 | 0.02 | 0.033 | Peptide deformylase inhibitor | 0.033 0.018 DBMET01896 | DBMET01896 | |
| 0.02 | 0.009 | 0.02 | Complement factor D inhibitor | |||
| 0.041 | 0.03 | 0.041 | Sphingosine kinase 1 inhibitor | 0.041 0.029 DBMET01896 | ||
| 0.019 | 0.008 | 0.019 | Adenosine A2a receptor agonist | |||
| 0.07 | 0.059 | 0.07 | Adenosine A3 receptor antagonist | |||
| 0.055 | 0.045 | 0.055 | Aromatase inhibitor | |||
| 0.057 | 0.046 | 0.057 | Collagenase 3 inhibitor | |||
| 0.019 | 0.009 | 0.019 | Adenosine A2 receptor agonist | |||
| 0.033 | 0.024 | 0.033 | Calcitonin receptor agonist | |||
| 0.037 | 0.028 | 0.037 | TRPM8 blocker | |||
| 0.051 | 0.042 | 0.051 | Acetylcholine muscarinic agonist | |||
| 0.046 | 0.037 | 0.046 | Cholesterol esterase inhibitor | |||
| 0.057 | 0.048 | 0.057 | TRPA1 antagonist | |||
| 0.067 | 0.058 | 0.067 | Epoxide hydrolase inhibitor | |||
| 0.077 | 0.069 | 0.077 | GABA A receptor agonist | |||
| 0.051 | 0.043 | 0.051 | Carbonic anhydrase II inhibitor | |||
| 0.036 | 0.028 | 0.036 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | |||
| 0.043 | 0.035 | 0.043 | Dipeptidyl peptidase IV inhibitor | |||
| 0.019 | 0.012 | 0.019 | Alpha 2b adrenoreceptor agonist | |||
| 0.019 | 0.012 | 0.019 | Alpha 2c adrenoreceptor agonist | |||
| 0.018 | 0.011 | 0.018 | CC chemokine 9 receptor antagonist | |||
| 0.057 | 0.05 | 0.057 | NMDA 2C receptor antagonist | |||
| 0.014 | 0.008 | 0.014 | Cyclin D2 inhibitor | |||
| 0.026 | 0.019 | 0.026 | Kynurenine 3 monooxygenase inhibitor | |||
| 0.05 | 0.044 | 0.05 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.032 | 0.026 | 0.032 | Carboxypeptidase B inhibitor | 0.03 0.029 DBMET01896 | ||
| 0.037 | 0.032 | 0.037 | Leukotriene C4 antagonist | |||
| 0.04 | 0.034 | 0.04 | HIV-1 protease inhibitor | |||
| 0.089 | 0.084 | 0.089 | Cyclin-dependent kinase 2 inhibitor | |||
| 0.129 | 0.124 | 0.129 | Antipruritic | |||
| 0.022 | 0.016 | 0.022 | Geranylgeranyltransferase inhibitor | |||
| 0.012 | 0.006 | 0.012 | Imidazoline I2 receptor antagonist | |||
| 0.038 | 0.033 | 0.038 | CDK5/p25 inhibitor | |||
| 0.009 | 0.004 | 0.009 | DNA topoisomerase III inhibitor | 0.007 0.005 DBMET01897 0.007 0.005 DBMET01898 | ||
| 0.008 | 0.003 | 0.008 | CC chemokine 6 receptor agonist | 0.007 0.004 DBMET01897 | ||
| 0.028 | 0.023 | 0.028 | Glucagon receptor antagonist | |||
| 0.026 | 0.021 | 0.026 | Myristoyl transferase inhibitor | |||
| 0.045 | 0.04 | 0.045 | Adenosine A2b receptor antagonist | |||
| 0.045 | 0.04 | 0.045 | Benzodiazepine antagonist | |||
| 0.072 | 0.068 | 0.072 | Acetylcholine nicotinic agonist | |||
| 0.026 | 0.021 | 0.026 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.032 | 0.027 | 0.032 | Glutamate (mGluR4) agonist | |||
| 0.047 | 0.042 | 0.047 | CD45 antagonist | |||
| 0.03 | 0.026 | 0.03 | Sirtuin 2 inhibitor | |||
| 0.039 | 0.035 | 0.039 | Sphingosine 1-phosphate receptor 1 agonist | |||
| 0.08 | 0.076 | 0.228 | Phosphodiesterase I inhibitor | 0.228 0.008 DBMET01897 | DBMET01897 | |
| 0.024 | 0.021 | 0.026 | Thyroid hormone agonist | 0.026 0.017 DBMET01896 | DBMET01896 | |
| 0.053 | 0.049 | 0.053 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | |||
| 0.042 | 0.039 | 0.042 | Glycine transporter inhibitor | |||
| 0.023 | 0.02 | 0.023 | Prostaglandin H2 antagonist | |||
| 0.01 | 0.006 | 0.01 | Progesterone receptor A antagonist | |||
| 0.108 | 0.105 | 0.108 | Toll-Like receptor antagonist | |||
| 0.072 | 0.07 | 0.072 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.038 | 0.035 | 0.038 | Acetylcholine M1 receptor agonist | |||
| 0.01 | 0.008 | 0.01 | Purinergic P2Y2 agonist | |||
| 0.036 | 0.034 | 0.036 | Protein kinase (CK1) epsilon inhibitor | |||
| 0.017 | 0.015 | 0.017 | CXC chemokine 5 receptor antagonist | |||
| 0.009 | 0.007 | 0.009 | Corticotropin releasing factor antagonist | |||
| 0.014 | 0.012 | 0.014 | NMDA receptor phencyclidine site antagonist | |||
| 0.026 | 0.024 | 0.026 | Thrombin receptor antagonist | |||
| 0.011 | 0.009 | 0.011 | Purine nucleoside phosphorylase inhibitor | |||
| 0.054 | 0.053 | 0.054 | Cyclin A2 inhibitor | |||
| 0.111 | 0.109 | 0.111 | Activin receptor-like kinase 2 inhibitor | |||
| 0.051 | 0.049 | 0.051 | MAP kinase kinase 9 inhibitor | |||
| 0.01 | 0.009 | 0.01 | Thromboxane agonist | |||
| 0.006 | 0.005 | 0.006 | Integrin alpha5beta6 antagonist | |||
| 0.034 | 0.033 | 0.034 | Glutamate (mGluR group II) antagonist | |||
| 0.039 | 0.038 | 0.039 | Neurokinin 3 antagonist | |||
| 0.015 | 0.016 | 0.017 | Aminopeptidase A inhibitor | 0.017 0.013 DBMET01896 | DBMET01896 | |
| 0.033 | 0.036 | 0.046 | Kainate receptor antagonist | 0.046 0.024 DBMET01896 | DBMET01896 | |
| 0.035 | 0.039 | 0.042 | Carbonic anhydrase IV inhibitor | 0.042 0.031 DBMET01896 | DBMET01896 | |
| 0.041 | 0.048 | 0.064 | Ribonucleoside-diphosphate reductase inhibitor | 0.064 0.032 DBMET01896 | DBMET01896 | |
| 0.02 | 0.026 | 0.022 | ICAM 1 antagonist | 0.022 0.019 DBMET01896 | DBMET01896 | |
| 0.042 | 0.049 | 0.066 | Ribonucleotide reductase inhibitor | 0.066 0.033 DBMET01896 | DBMET01896 | |
| 0.033 | 0.041 | 0.038 | Histone deacetylase 9 inhibitor | 0.038 0.03 DBMET01896 | DBMET01896 | |
| 0.08 | 0.091 | 0.249 | Monophenol monooxygenase inhibitor | 0.097 0.078 DBMET01896 0.249 0.024 DBMET01897 | DBMET01897 | |
| 0.043 | 0.053 | 1 | Cathepsin D inhibitor | 1 0 DBMET01897 | DBMET01897 | |
| 0.026 | 0.056 | 0.041 | Antibiotic Aminoglycoside-like | 0.041 0.02 DBMET01896 | DBMET01896 | |
| 0.028 | 0.059 | 0.128 | Phosphorylase inhibitor | 0.128 0.009 DBMET01897 | DBMET01897 | |
| 0.026 | 0.076 | 0.1 | Stearoyl-CoA desaturase inhibitor | 0.1 0.007 DBMET01897 | DBMET01897 | |
| 0.034 | 0.13 | 0.067 | Histone deacetylase inhibitor | 0.067 0.043 DBMET01896 | DBMET01896 | |
| 0.052 | 0.227 | 0.999 | Phosphodiesterase inhibitor | 0.999 0 DBMET01897 | DBMET01897 | |
| 0.019 | 0.275 | 1 | Guanylate cyclase stimulant | 1 0 DBMET01898 | DBMET01898 | |
| 0.014 | 0.418 | 1 | Nitric oxide donor | 0.06 0.048 DBMET01896 1 0 DBMET01898 | DBMET01898 | |
| 0.002 | 0.933 | 0.171 | Protein 30S ribosomal subunit inhibitor | 0.171 0.001 DBMET01897 | DBMET01897 | |
| 0.006 | 0.957 | 0.285 | Immunosuppressant | 0.285 0.125 DBMET01896 | DBMET01896 | |
| 0.006 | 0.996 | 0.279 | Death-associated protein kinase 2 inhibitor | 0.279 0.009 DBMET01896 | DBMET01896 | |
| 0.003 | 0.995 | 0.071 | Acid-sensing ion channel blocker | 0.071 0.005 DBMET01896 | DBMET01896 | |
| 0.002 | 0.996 | 0.233 | Thrombin inhibitor | 0.233 0.005 DBMET01896 | DBMET01896 | |
| 0.001 | 0.999 | 0.11 | Leukotriene synthesis inhibitor | 0.11 0.021 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.117 | Aminopeptidase microsomal inhibitor | 0.117 0.014 DBMET01896 | DBMET01896 | |
| 0.001 | 0.999 | 0.085 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.085 0.056 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.101 | Aminopeptidase N inhibitor | 0.101 0.013 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.086 | Trypsin inhibitor | 0.086 0.024 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.172 | Neuraminidase inhibitor | 0.172 0.005 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.114 | Histone deacetylase 6 inhibitor | 0.114 0.007 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.115 | Histone deacetylase class IIb inhibitor | 0.115 0.007 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.046 | Trypsin I inhibitor | 0.046 0.014 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.12 | Histone deacetylase 1 inhibitor | 0.12 0.008 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.147 | Histone deacetylase 2 inhibitor | 0.147 0.008 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.068 | Histone deacetylase 3 inhibitor | 0.068 0.009 DBMET01896 | DBMET01896 | |
| 0 | 0.999 | 0.134 | Histone deacetylase class II inhibitor | 0.134 0.006 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.057 | Collagenase inhibitor | 0.057 0.02 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.062 | Histone deacetylase 4 inhibitor | 0.062 0.009 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.106 | Histone deacetylase class IIa inhibitor | 0.106 0.008 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.116 | Histone deacetylase 5 inhibitor | 0.116 0.008 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.195 | Farnesoid X receptor antagonist | 0.195 0.023 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.15 | Death-associated protein kinase 1 inhibitor | 0.15 0.039 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.158 | Lipocortins synthesis antagonist | 0.158 0.094 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.063 | Histone deacetylase class IV inhibitor | 0.063 0.01 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.063 | Histone deacetylase 11 inhibitor | 0.063 0.01 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.06 | Histone deacetylase 10 inhibitor | 0.06 0.009 DBMET01896 | DBMET01896 | |
| 0 | 1 | 0.022 | Retinoic acid gamma receptor agonist | 0.022 0.017 DBMET01896 | DBMET01896 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |